Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients

NEW YORK, Jan. 18, 2024. Hoth Therapeutics, Inc., a patient-focused biopharmaceutical company, announced today that it has received U.S. Food and Drug Administration (FDA) clearance to implement a number of protocol amendments to its ongoing...
Source: Drugs.com - Clinical Trials - Category: Pharmaceuticals Source Type: clinical trials